Publications by authors named "Zaragoza-Ninet V"
Background: Abrocitinib, a selective JAK 1 inhibitor, was recently approved in Europe. Despite its approval, real-world data on its efficacy and safety in treating moderate-to-severe atopic dermatitis (AD) remains limited.
Objectives: This study aimed to evaluate the short-term effectiveness and safety of abrocitinib in a real-life setting for patients with moderate-to-severe AD.
Article Synopsis
- - A study evaluated the effectiveness and safety of dupilumab for treating bullous pemphigoid in elderly patients, with a focus on those who typically have other health issues that make standard treatments unsuitable.
- - The results showed that 53.4% of patients achieved complete remission within 4 weeks and 95.7% by week 52, with a significant reduction in itchiness and a dramatic decrease in the need for corticosteroids.
- - The treatment was found to be safe, with most adverse events being mild, and factors like shorter disease duration and exclusive skin involvement were linked to better treatment responses.
Article Synopsis
- Patch test outcomes can be affected by age, but there are mixed findings on how age impacts these results.
- The study involved over 13,000 patients and revealed that middle-aged adults (31-65 years) had the highest rates of positive skin sensitisation results, particularly for certain substances like nickel and potassium dichromate.
- Overall, while age does influence some patch test results, most allergens showed consistent reactivity across ages, underscoring the importance of standard testing regardless of age.
Article Synopsis
- Severe recurrent aphthous stomatitis (RAS) significantly affects quality of life, and currently, no approved systemic treatments exist, prompting the exploration of roflumilast, a phosphodiesterase-4 inhibitor.
- In a study involving 22 RAS patients across five Spanish centers, roflumilast treatment resulted in substantial improvements, including an 88% reduction in flare-ups and a 94% decrease in oral ulcers over 12 weeks.
- Despite some adverse effects (mainly headache and gastrointestinal issues), roflumilast was generally well tolerated, showing promise as an effective and safe treatment option for RAS.
Background: Reports of allergic contact dermatitis (ACD) to phytonadione epoxide (PE) in cosmetics suggest that PE is as powerful a sensitiser as its parent compound phytonadione.
Objective: To evaluate a case series of ACD to PE in Spain.
Methods: We reviewed the records of 20 patients with ACD to cosmetics containing PE diagnosed across Spain between January 2019 and June 2023.
Article Synopsis
- Atopic dermatitis (AD) and allergic contact dermatitis (ACD) are different inflammatory skin conditions, and the study aimed to explore their relationship further among patients referred for patch testing.
- Researchers analyzed data from the Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy (REIDAC) to compare contact allergies and other clinical details between patients with AD and those without.
- The study found that while both groups showed similar allergy profiles, patients with AD had a lower likelihood of being sensitized to nickel sulphate compared to non-AD patients.
Background: Mucocutaneous Behçet disease often presents a therapeutic challenge. Roflumilast has shown promise in the treatment of other inflammatory dermatological conditions.
Objectives: The objective of this study was to evaluate the characteristics, effectiveness and safety of roflumilast in the treatment of Behçet disease-associated aphthosis in routine clinical practice.
We present the case of a 53-year-old Caucasian man with a history of intravenous drug use who presented with fever and multiple pustules predominantly affecting hairy areas of the body, with no clinical improvement despite previous antibiotic treatment. Culture of the pustules confirmed Candida albicans infection and histological examination of skin biopsies revealed suppurative granulomas compatible with candidomycetic folliculitis. The patient was successfully treated with systemic antifungals and discharged with resolution of symptoms.
View Article and Find Full Text PDFAfter the meeting held by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) back in October 2021, changes were suggested to the Spanish Standard Series patch testing. Hydroxyethyl methacrylate (2% pet.), textile dye mixt (6.
View Article and Find Full Text PDFBackground: Psoriasis is a chronic inflammatory dermatosis whose clinical and topographic distribution requires differential diagnosis, or the possible association with allergic contact dermatitis (ACD), requiring patch testing (PT) as part of the diagnostic procedure.
Objectives: To describe the epidemiological, clinical, and allergic profile of patients with a primary or secondary diagnosis of psoriasis undergoing PT and compare them with patients with a diagnosis of ACD at the end of the diagnostic process.
Methods: Cross-sectional study with data from REIDAC from 2018 through 2023 of selected patients with a diagnosis of psoriasis and/or ACD.
Article Synopsis
- A multicentric study in Spain analyzed data from 10,176 patients over four years to explore polysensitization (PS), finding that 8.3% of participants were polysensitized.
- Factors associated with PS included older age, atopic dermatitis, and exposure at specific body locations, with significant differences in allergen relevance compared to those with fewer sensitivities.
- The research revealed distinct allergen clusters among polysensitized patients, suggesting that cross-reactivity and sensitization may contribute to these patterns.
Background: A global epidemic of allergic contact dermatitis to (meth)acrylates has been described in relation to the widespread use of manicure products.
Objectives: To evaluate the frequency of sensitization to 2-hydroxyethyl methacrylate (2-HEMA) among consecutively patch tested patients with eczema in Spain; the percentage of current relevance; the MOAHLFA index; and, the potential sources of exposure to (meth)acrylates.
Methods: From January 2019 to December 2022, 2-HEMA 2% pet.
Background: Current frequency and features for positivity to textile dye mix (TDM) in Spain are unknown.
Objectives: To study the frequency, clinical features and simultaneous positivity between TDM, para-phenylenediamine (PPD) and specific disperse dyes.
Materials And Methods: We analysed all consecutive patients patch-tested with TDM from the Spanish Contact Dermatitis Registry (REIDAC), from 1 January 2019 to 31 December 2022.
Background: The epidemiological surveillance of contact dermatitis is one of the objectives of the Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy. Knowing whether the prevalence of positive tests to the different allergens changes over time is important for this monitoring process.
Objectives: To describe the various temporary trends in allergen positivity in the GEIDAC standard series from 2018 through December 31, 2022.
Background: Dupilumab is a new targeted therapy for severe atopic dermatitis (AD) with limited real-world evidence.
Objective: Explore our experience with dupilumab for AD in clinical practice at a tertiary care center.
Material And Method: Unicentric observational retrospective study including adult and pediatric patients with severe AD receiving dupilumab between December 2017 and December 2021.
Background: Dupilumab is a new targeted therapy for severe atopic dermatitis (AD) with limited real-world evidence.
Objective: Explore our experience with dupilumab for AD in clinical practice at a tertiary care center.
Material And Method: Unicentric observational retrospective study including adult and pediatric patients with severe AD receiving dupilumab between December 2017 and December 2021.